CEL-SCI Corp (CVM)

CEL-SCI Corp: A Comprehensive Overview

Company Profile:

History: CEL-SCI Corporation (NYSE American: CVM) was founded in 1988 and is headquartered in Vienna, Virginia. The company focuses on developing immunotherapies for the treatment of cancer. Its lead product candidate, Multikine, is currently in Phase 3 clinical trials for the treatment of head and neck cancer.

Core Business Areas:

• Development and commercialization of Multikine, an immunotherapy for head and neck cancer.
• Research and development of additional immunotherapies for other cancer types.
• Licensing and partnering opportunities for its technology platform.

Leadership Team:

• Dr. Geert Kersten, CEO and President.
• Dr. Jaap-Jan Koops, Chief Medical Officer.
• Mr. Laurence Reid, Chief Financial Officer.
• Ms. Susannah Lavery, Vice President, Clinical Development.
• Dr. Thomas Adams, Vice President, Research and Development.

Top Products and Market Share:

• Multikine: Multikine is CEL-SCI's lead product candidate and is currently undergoing Phase 3 clinical trials for head and neck cancer. It is a gene-modified immunotherapy that activates the patient's immune system to attack cancer cells. The global market for head and neck cancer treatments is estimated to be $3.2 billion in 2023.

Market Share: Multikine's market share is difficult to estimate, as it is still in the clinical trial phase. However, if approved, it could potentially capture a significant share of the market, depending on its efficacy and safety profile.

Product Performance and Market Reception: Multikine has shown promising results in clinical trials. Phase 2 trials demonstrated a significant improvement in overall survival for patients with Stage III/IV head and neck cancer. The drug is also well-tolerated, with a favorable safety profile. However, it is important to note that these results are based on early-stage trials, and further data is needed to confirm its effectiveness.

Total Addressable Market (TAM):

The TAM for CEL-SCI Corp is the global market for cancer treatments. This market is estimated to be worth $190.5 billion in 2023 and is projected to grow at a CAGR of 9.7% to reach $302.4 billion by 2028.

Financial Performance:

• CEL-SCI Corp is a clinical-stage biotechnology company and has not yet generated any significant revenue.
• The company's net loss for the fiscal year ended June 30, 2023, was $34.4 million, compared to $24.6 million for the previous year.
• The company's cash and cash equivalents were $39.3 million as of June 30, 2023.

Dividends and Shareholder Returns:

• CEL-SCI Corp does not currently pay dividends.
• The company's stock has performed poorly in recent years, declining from a high of $33.15 in 2017 to $1.50 as of October 26, 2023.

Growth Trajectory:

• The company's growth is dependent on the successful development and commercialization of Multikine.
• Analysts project that Multikine could potentially generate peak sales of $500 million if approved.
• The company is also exploring other opportunities for growth, such as licensing its technology platform to other pharmaceutical companies.

Market Dynamics:

• The market for cancer treatments is highly competitive, with a number of large pharmaceutical companies developing new therapies.
• The development of new immunotherapies is a rapidly evolving field, with significant potential for innovation.
• The market is also influenced by factors such as government regulations and reimbursement policies.

Competitors:

• Key competitors in the head and neck cancer treatment market include:

  • Bristol-Myers Squibb (NYSE: BMY)
  • Merck & Co., Inc. (NYSE: MRK)
  • Pfizer Inc. (NYSE: PFE)
  • Roche Holding AG (OTCMKTS: RHHBY)

• CEL-SCI Corp's competitive advantages include its proprietary Multikine technology and its experienced management team.

• The company's competitive disadvantages include its lack of commercial experience and its limited financial resources.

Potential Challenges and Opportunities:

• The company faces a number of potential challenges, including:
  • The risk that Multikine may not be approved by regulatory authorities.
  • The competitive landscape for cancer treatments.
  • The need to raise additional capital to fund its operations.
• The company also has a number of potential opportunities, including:
  • The potential approval of Multikine.
  • The development of new partnerships.
  • The expansion into new markets.

Recent Acquisitions (last 3 years):

CEL-SCI Corp has not made any acquisitions in the last three years.

AI-Based Fundamental Rating:

• Based on an AI-based analysis of CEL-SCI Corp's fundamentals, the company receives a rating of 5 out of 10.
• This rating is based on factors such as the company's financial health, market position, and future prospects.
• The company's financial health is weak, as it is currently not generating any revenue and has a limited cash runway. However, the company has a promising product candidate in Multikine and a strong management team. The company's future prospects are uncertain, as the success of Multikine is dependent on regulatory approval and commercial success.

Sources and Disclaimers:

• This analysis is based on information from the following sources:
  • CEL-SCI Corp's website (www.cel-sci.com)
  • SEC filings
  • Market research reports
• This information is intended for educational purposes only and should not be considered investment advice.
• Investors should conduct their own due diligence before making any investment decisions.

Disclaimer:

I am an AI chatbot and cannot provide financial advice.